| Status | In progress |
| Process | STA 2018 |
| ID number | 3816 |
Provisional Schedule
| Committee meeting: 1 | 09 November 2021 |
| Expected publication | 02 February 2022 |
Project Team
| Project lead | Louise Jafferally |
Email enquiries
- If you have any queries please email TATeam4@nice.org.uk
| Evidence Review Group / Assessment Group | Centre for Reviews and Dissemination and Centre for Health Economics, University of York |
Consultees
| Companies sponsors | Janssen (ciltacabtagene autoleucel) |
| Others | Department of Health and Social Care |
| NHS England | |
| NHS Lambeth CCG | |
| NHS Waltham Forest CCG | |
| Welsh Government | |
| Patient carer groups | African Caribbean Leukaemia Trust |
| Anthony Nolan | |
| Black Health Agency for Equality | |
| Blood Cancer UK | |
| Cancer Black Care | |
| Cancer Equality | |
| Cancer52 | |
| DKMS | |
| Helen Rollason Cancer Charity | |
| Independent Cancer Patients Voice | |
| Leukaemia Cancer Society | |
| Leukaemia Care | |
| Macmillan Cancer Support | |
| Maggie’s Centres | |
| Marie Curie | |
| Myeloma UK | |
| South Asian Health Foundation | |
| Specialised Healthcare Alliance | |
| Tenovus Cancer Care | |
| Professional groups | Association of Cancer Physicians |
| British Blood Transfusion Society | |
| British Committee for Standards in Haematology | |
| British Geriatrics Society | |
| British Institute of Radiology | |
| British Psychosocial Oncology Society | |
| British Society for Haematology | |
| British Society for Interventional Radiology | |
| British Transplantation Society | |
| Cancer Research UK | |
| NHS Blood and Transplant | |
| Royal College of General Practitioners | |
| Royal College of Nursing | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Royal Pharmaceutical Society | |
| Royal Society of Medicine | |
| Society and College of Radiographers | |
| UK Clinical Pharmacy Association | |
| UK Myeloma Forum | |
| UK Oncology Nursing Society |
Commentators
| Associated guideline groups | National Guideline Alliance |
| Associated public health groups | Public Health England |
| Public Health Wales | |
| Comparator companies | Advanz pharma (dexamethasone) |
| Amgen (carfilzomib) | |
| Aspen (dexamethasone) | |
| Aspire pharma (bortezomib, dexamethasone) | |
| Celgene (lenalidomide, pomalidomide) | |
| Consilient health (dexamethasone) | |
| Dr Reddy’s laboratories (bortezomib) | |
| Glenmark pharmaceuricals (dexamethasone) | |
| Janssen-Cilag (bortezomib) | |
| Martindale pharma (dexamethasone) | |
| Mylan (bortezomib) | |
| Novartis pharmaceuticals (panobinostat) | |
| Teva (dexamethasone) | |
| Thornton & Ross (bortezomib) | |
| Rosemont pharmaceuticals limited (dexamethasone) | |
| Zentiva (bortezomib) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| Allied Health Professionals Federation | |
| Board of Community Health Councils in Wales | |
| British National Formulary | |
| Care Quality Commission | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare Products Regulatory Agency | |
| National Association of Primary Care | |
| National Pharmacy Association | |
| NHS Alliance | |
| NHS Confederation | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Cochrane Haematological Malignancies Group |
| Genomics England | |
| Institute of Cancer Research | |
| Leukaemia UK | |
| Leukaemia Busters | |
| MRC Clinical Trials Unit | |
| National Cancer Research Institute | |
| National Cancer Research Network | |
| National Institute for Health Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 12 March 2021 | Invitation to participate |
| 14 January 2021 - 11 February 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 17 March 2020 | In progress. DHSC referral received |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance